

Answer 1:

Bibliographic Information

Antitumor activity of a new antiestrogenic drug, Toremifene citrate (NK622) against human breast cancer xenografts in nude mice. Kuroiwa, Shunsuke; Koyama, Michinori; Watanabe, Noriko; Ekimoto, Hisao; Ohnishi, Yasuyuki; Saito, Muneo; Maruo, Kohji; Inaba, Makoto; Tashiro, Tazuko; et al. Res. Lab., Nippon Kayaku Co., Ltd., Japan. Gan to Kagaku Ryoho (1993), 20(5), 617-2. CODEN: GTKRDX ISSN: 0385-0684. Journal written in Japanese. CAN 119:85544 AN 1993:485544 CAPLUS (Copyright (C) 2008 ACS on SciFinder (R))

Abstract

NK622, a novel tamoxifen (TAM) analog with a nonsteroidal structure is an antiestrogenic drug with less toxicity than that of TAM. The in vivo antitumor activity of NK622 against human breast cancer xenografts in nude mice was studied. NK622 significantly inhibited the growth of estrogen-dependent Br-10 breast cancer but did not inhibit the growth of estrogen-independent MC-2-JCK and MC-5-JCK cells when orally administered once daily for 14 days at the max. tolerated dose (200 mg/kg/day). The dose of NK622 for animal studies was calcd. by measuring plasma levels in patients receiving 40 mg/body/day oral treatment and detg. the clin. equiv. dose (CED). At the calcd. CED, NK622 significantly inhibited the growth of Br-10. These results indicate that NK622 is a promising drug, comparable to TAM, for the treatment of estrogen-dependent breast cancers.